EUCTR2021-000898-83-IT进行中（未招募）1 期
A phase II, randomized, double-blind, placebo-controlled, two-period, crossover trial to assess the efficacy and safety of begelomab in combination with standard steroid and/or immunosuppressant therapy in the treatment of patients with dermatomyositis - ADN016
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- ADIENNE SA
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent before starting any study-related procedure;
- •-Males and Females aged > or = 18 and < or = 80 years old;
- •-Diagnosis of probable or definite DM according to Bohan and Peter criteria (Bohan and Peter, 1975) or ACR/EULAR criteria (Lundberg et al, 2017);
- •-Although not mandatory, patients with muscle weakness are eligible for enrollment. Those with active muscle weakness must have a Manual Muscle Testing (MMT-8) score < 142 out of 150;
- •-Active skin disease as defined by a CDASI score > or = 5;
- •-Stable glucocorticoid treatment for DM at a stable dose < or = 0.2 mg/kg/day methylprednisolone or prednisolone or equivalent for > or = 4 weeks before randomization;
- •-Stable immunosuppressant treatment for DM for > or = 4 weeks before randomization, the stable treatment is defined as follows:
- •o Patients currently treated with oral or subcutaneous methotrexate (MTX) must have been on a stable dose < or = 25 mg per week.
- •o Patients currently treated with oral azathioprine (AZA) must have been on a stable dose < or = 3 mg/kg/day.
- •o Patients currently treated with oral mycophenolate (MMF) must have been on a stable dose < or = 3 g/day.
- •o Patients currently treated with oral, subcutaneous or intravenous Cyclosporine (CsA) must have been on a stable dose of < or = 5 mg/kg/day.
- •-Patients that have received the following treatments can be enrolled only if the medications have been discontinued prior to screening visit:
- •o Rituximab: 9 months (Note: patients who received rituximab are only eligible for inclusion if B-cell counts are confirmed to be within normal limits)
- •o Intravenous immunoglobulin (IVIG): 3 months
- •-Female subjects must meet one of the following criteria:
- •o Surgical sterilization (complete hysterectomy, bilateral tubal ligation and/or bilateral ovariectomy or tubal occlusion at least 6 months prior to first dosing), or have documented congenital sterility.
- •o Postmenopausal: defined as at least 12 months with no menses prior to screening and a serum follicle-stimulating hormone (FSH) to confirm postmenopausal status at screening.
- •o Women of child-bearing potential must agree to take adequate contraceptive measures in order to avoid any pregnancies during the course of the study (or for at least 3 months following the last dose of study drug, whichever is longer). Acceptable methods of birth control include oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/ film/ cream/suppository. Abstinence is only considered an acceptable form of contraception when
- •it is the usual life style of an individual.
- •-Male patient who is surgically sterile (vasectomy), or male patient who is willing to agree with the true abstinence (refrain from heterosexual intercourse) or who uses barrier contraceptive measures during the entire study treatment period and for 3 months after the last administration of study drug. It is also acceptable where patient partner is making use of oral contraceptive instead.
- •-Women must have a negative pregnancy test at Screening and at Baseline and must not be breastfeeding.
- •-Subject must be willing and able to comply with study requirements, remain at the clinic, and return to the clinic for the follow-up evaluation, as specified in this protocol during the study period.
- •Are the trial subjects under 18? no
排除标准
- •- Any systemic corticosteroid therapy for indication other than DM in the last 4 weeks before the enrolment; the application of topical steroids is allowed.
- •- Patients with other types of myositis or myopathies: polymyositis, inclusion body myositis, necrotizing myopathy, metabolic or drug induced myopathy or myositis in overlap with other rheumatic diseases such as lupus, scleroderma, Sjogren's, or vasculitis.
- •-Any of the following laboratory values at Screening:
- •o Haemoglobin < 9 g/dL in males and < 8 g/dL in females
- •o White blood cell count < 3.0 × 10^9/L
- •o Absolute neutrophil count (ANC) < 1.2 × 10^9 /L (1200/mm^3)
- •o Platelet count < 75 × 10^9 /L
- •o Serum AST or serum ALT > 2.5 × ULN (unless considered consistent with muscle origin)
- •-Major surgery within 12 weeks before Screening or planned during the study period.
- •-Any active or suspected malignancy, including myeloproliferative or lymphoproliferative disorder, or history of documented malignancy within the last 5 years before screening or within 3 years of diagnosis of myositis, except appropriately excised and cured cervical carcinoma in situ or basal or squamous cell carcinoma of the skin.
- •- Any underlying or current medical or psychiatric condition that, in the opinion of the investigator, would interfere with the evaluation of the subject including, but not limited to symptomatic congestive heart failure (New York Heart Association [NYHA] Class III to IV), unstable angina pectoris or cardiac arrhythmia. Any other serious medical condition, as judged by the investigator, which places the subject at an unacceptable risk if he or she were to participate in the study or confounds the ability to interpret data from the study.
- •-Patients with uncontrolled bacterial, viral or fungal infections.
- •-Administration of any other investigational agents (not approved by the United States Food and Drug Administration Agency [FDA] or European Medicines Agency [EMA] for any indication) within 4 weeks prior to enrolment.
- •-Clinically significant history of any drug sensitivity, drug allergy, or food allergy, as determined by the Investigator.
- •-History of chronic drug or alcohol abuse within the last 5 years
- •-Patients unable to understand the procedures and purposes of the study or unwilling to accept and meet study requirements.
- •-Unwillingness to use effective contraceptive measures up to 3 months after the end of study drug administration (females and males). Acceptable methods of birth control include oral, injected or implanted hormonal methods of contraception, placement of an intrauterine device IUD) or intrauterine system (IUS), barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository. Abstinence is only considered an acceptable form of contraception when it is the usual life style of an individual.
研究者
相似试验
尚未招募
2 期
A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH)prostate hyperplasia10046590NL-OMON31439Organon Nederland BV36
进行中（未招募）
不适用
A clinical trial to evaluate whether Neovacs' TNFa-Kinoid is effective andsafe for treating adult subjects with moderate to severe Crohn's DiseaseEUCTR2010-019996-32-DEeovacs SA132
进行中（未招募）
1 期
A phase II, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of UK-500,001 Dry Powder for Inhalation (DPI) in adults with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).EUCTR2005-003713-32-ESPfizer SA200
进行中（未招募）
不适用
A phase II, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Org 3236 tablets in men with Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH)MedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaBenign prostatic hyperplasiaEUCTR2007-005793-31-GBV Organon240
进行中（未招募）
不适用
A clinical trial to evaluate whether Neovacs' TNFa-Kinoid is effective andsafe for treating adult subjects with moderate to severe Crohn's DiseaseModerate to severe Crohn's DiseaseMedDRA version: 14.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2010-019996-32-BGeovacs SA132